Pneumocystis jiroveci : still troublesome to diagnose and treat.
Maddalena Peghin, Jay A Fishman, Paolo Antonio Grossi
https://pubmed.ncbi.nlm.nih.gov/41151592/Actively Recruiting
Led by Mundipharma Research Limited · Updated on 2025-04-03
50
Participants Needed
6
Research Sites
13 weeks
Total Duration
This research aims to evaluate the effectiveness, safety, and tolerability of rezafungin combined with 7 days of co-trimoxazole compared to co-trimoxazole alone for treating Pneumocystis pneumonia PCP in adults living with HIV. The study is a Phase 2, open-label, randomized trial designed to expand knowledge about the clinical use of rezafungin in this population. Participants are adults diagnosed with definitive, presumptive, or clinically suspected PCP and living with HIV. The study includes a Screening period from Day -2 to Day -1, a Treatment period from Day 1 to Day 21, and a Follow-up visit around Day 50. Participants are randomly assigned to one of two groups one group receives weekly intravenous rezafungin infusions on Days 1, 8, and 15 combined with 7 days of oral or IV co-trimoxazole, while the other group receives co-trimoxazole alone for 21 days. Dosing adjustments for co-trimoxazole are made for participants with reduced kidney function. After the treatment period, all participants receive secondary prophylaxis against PCP following local guidelines. Throughout the study, participants will be monitored for adverse events and treatment response, including the rates of PCP relapse or immune reconstitution inflammatory syndrome. Safety assessments include vital signs, laboratory tests blood counts, chemistry, urinalysis, physical exams, and heart monitoring with ECGs. Medication use will be recorded. The total participation duration is approximately 52 days, ending with a follow-up visit to evaluate outcomes and safety.
CONDITIONS
Rezafungin for Treatment of Pneumocystis Pneumonia in HIV Adults
E
Elizabeth Chong, MSc
T
Terry Nichols
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Mundipharma Research Limited
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for screening and enrollment
Duration - 21 days
Participants receive study drugs to treat Pneumocystis pneumonia, including either rezafungin combined with co-trimoxazole or co-trimoxazole alone.
3 intravenous infusion visits on Days 1, 8, and 15 plus daily oral or intravenous medication from Day 1 to Day 21
Duration - 1 day
Participants have a follow-up visit to evaluate adverse events, treatment response, and rates of relapse or immune reconstitution inflammatory syndrome.
1 visit on Day 50 (±2 days)
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Maddalena Peghin, Jay A Fishman, Paolo Antonio Grossi
https://pubmed.ncbi.nlm.nih.gov/41151592/Mundipharma Research Limited
Lead Sponsor